Lv31
340 积分 2024-09-26 加入
A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial
2小时前
待确认
Gut microbiome pattern reflects healthy ageing and predicts survival in humans
4小时前
已完结
Circulating tumor DNA in conjunctival melanoma: landscape and surveillance value
4天前
已完结
Genetic characterization of advanced conjunctival melanoma and response to systemic treatment
5天前
已完结
Tumor-Microenvironment-Activatable Nanoparticle Mediating Immunogene Therapy and M2 Macrophage-Targeted Inhibitor for Synergistic Cancer Immunotherapy
7天前
已完结
Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment
10天前
已完结
Host–microbiota maladaptation in colorectal cancer
20天前
已完结
CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy
21天前
已完结
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
29天前
已完结
Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers
1个月前
已完结
皖公网安备34019202002308
